查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
膀胱癌市場:KOL的洞察
市場調查報告書
商品編碼
1796157

膀胱癌市場:KOL的洞察

KOL Insight - Bladder Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入分析了膀胱癌標靶治療的不斷發展，重點關注已上市和後期研發產品。基於對北美和歐洲關鍵意見領袖的訪談，報告探討了目前的治療標準、檢查點抑制劑和抗體藥物偶聯物的臨床影響，以及基因治療和新型免疫調節劑等新興療法的潛力。深入了解專家對治療選擇的看法、患者特徵的影響、正在進行和即將進行的臨床試驗的重要性，以及新數據和技術創新推動的治療途徑預期轉變。報告還探討了患者分層方面的挑戰、生物標記驅動方法的採用以及膀胱保留策略在臨床實踐中的未來作用。

關鍵問題解答

  • 1.目前建議的膀胱癌治療方法有哪些？為什麼？
  • 2.專家如何評估已核准的檢查點抑制劑在膀胱癌中的作用和影響？
  • 3.Padoseb（enformab vedotin）+ Keytruda（pembrolizumab）組合的臨床意義為何？
  • 4.皮下注射製劑如何影響膀胱癌治療？
  • 5.預計膀胱癌治療模式將如何隨著患者人口統計和治療線的變化而變化？
  • 6.哪些病患特徵對尿路上皮癌的治療方案影響最大？
  • 7.哪些正在進行的臨床試驗可能會影響未來的處方趨勢？
  • 8.研發產品必須達到哪些療效和安全性基準才能與目前的市場領導者競爭？

部分參與專家名單

  • 英國倫敦巴茲癌症中心泌尿生殖腫瘤學主任及教授
  • 荷蘭阿姆斯特丹大學醫學中心泌尿外科副教授
  • 法國巴黎索邦大學泌尿科教授（APHP）
  • 美國德州達拉斯德州大學西南醫院系統泌尿外科診所醫學主任
  • 美國佛羅裡達州坦帕市南佛羅裡達大學莫爾薩尼醫學院腫瘤內科教授
  • 加拿大安大略省多倫多市多倫多大學醫學院副教授、加拿大泌尿腫瘤學會主席

研究方法

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病的當前和未來治療前景。領域。關鍵意見領袖 (KOL) 的甄選是基於嚴格的標準，包括全球認可度、臨床專業知識以及在治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與關鍵意見領袖合作開發，並由行業專家進行同行評審，確保問題全面且與當前市場動態相關。每份報告發布後，我們會持續 12 個月的市場監測，及時提供關鍵意見領袖對重要新聞事件、市場變化和市場發展的更新。

我們的報告有何獨特之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶掌握新興趨勢並有效解決複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告可提供您所需的準確性和可靠性。獨家專訪和數據，以及持續的市場監測，確保您全面了解市場動態。我們的報告涵蓋 40 多個活躍疾病領域，包含 KOL 洞察和定量醫生調查等醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

This report provides an in-depth analysis of the evolving landscape of targeted therapies in bladder cancer, with a focus on both marketed and late-stage pipeline products. Drawing on interviews with leading key opinion leaders from North America and Europe, the report examines current standards of care, the clinical impact of checkpoint inhibitors and antibody-drug conjugates, and the potential of emerging therapies such as gene therapies and novel immunomodulators. Gain insights into expert perspectives on treatment selection, the influence of patient characteristics, the significance of ongoing and upcoming clinical trials, and the anticipated shifts in treatment pathways driven by new data and innovation. The report also addresses challenges in patient stratification, the adoption of biomarker-driven approaches, and the future role of bladder-sparing strategies in clinical practice.

Key Questions Answered:

  • 1. What are the current preferred therapies for bladder cancer and why?
  • 2. How do experts assess the role and impact of approved checkpoint inhibitors in bladder cancer?
  • 3. What is the clinical significance of the Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) combination?
  • 4. How could subcutaneous formulations affect bladder cancer treatment?
  • 5. How is the bladder cancer treatment landscape expected to evolve across patient segments and lines of therapy?
  • 6. Which patient characteristics most influence treatment selection in urothelial carcinoma?
  • 7. Which ongoing clinical trials are likely to impact future prescribing trends?
  • 8. What efficacy and safety benchmarks must pipeline products meet to compete with current market leaders?

Partial List of Participating Experts:

  • Director and Professor of Genitourinary Oncology at Barts Cancer Center, London, UK
  • Associate Professor of Urology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Professor of Urology, Sorbonne University APHP, Paris, France
  • Medical Director of the Urology Clinic at UT Southwestern Hospital System, Dallas, Texas, USA
  • Professor of Oncology and Internal Medicine at University of South Florida Morsani College of Medicine, Tampa, Florida, USA
  • Associate Professor of Medicine at the University of Toronto, Chair of the Genitourinary Medical Oncologists of Canada, Toronto, Ontario, Canada

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.